170 related articles for article (PubMed ID: 12854905)
21. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
22. Pralatrexate - from bench to bedside.
Zain JM; Marchi E
Drugs Today (Barc); 2010 Feb; 46(2):91-9. PubMed ID: 20393637
[TBL] [Abstract][Full Text] [Related]
23. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance.
Jansen G; Westerhof GR; Kathmann I; Rademaker BC; Rijksen G; Schornagel JH
Cancer Res; 1989 May; 49(9):2455-9. PubMed ID: 2706633
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
25. 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.
Sirotnak FM; Schmid FA; Samuels LL; DeGraw JI
NCI Monogr; 1987; (5):127-31. PubMed ID: 2448650
[TBL] [Abstract][Full Text] [Related]
26. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
Sirotnak FM; Otter GM; Schmid FA
Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
[TBL] [Abstract][Full Text] [Related]
27. Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
Cao S; Abraham A; Nair MG; Pati R; Galivan JH; Hausheer FH; Rustum YM
Clin Cancer Res; 1996 Apr; 2(4):707-12. PubMed ID: 9816221
[TBL] [Abstract][Full Text] [Related]
28. The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.
Visentin M; Unal ES; Zhao R; Goldman ID
Cancer Chemother Pharmacol; 2013 Sep; 72(3):597-606. PubMed ID: 23881211
[TBL] [Abstract][Full Text] [Related]
29. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
30. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Molina JR
IDrugs; 2008 Jul; 11(7):508-21. PubMed ID: 18600598
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice.
Kuehl M; Brixner DI; Broom AD; Avery TL; Blakley RL
Cancer Res; 1988 Mar; 48(6):1481-8. PubMed ID: 2449950
[TBL] [Abstract][Full Text] [Related]
32. Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models.
Sirotnak FM; Schmid FA; Otter GM; Piper JR; Montgomery JA
Cancer Res; 1988 Oct; 48(20):5686-91. PubMed ID: 3167828
[TBL] [Abstract][Full Text] [Related]
33. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the gamma-carboxyl group.
McGuire JJ; Russell CA; Bolanowska WE; Freitag CM; Jones CS; Kalman TI
Cancer Res; 1990 Mar; 50(6):1726-31. PubMed ID: 2306727
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and toxicity of 10-ethyl-10-deazaaminopterin and methotrexate in a mycobacterial rat arthritis model.
Skeith KJ; Ramos-Remus C; Russell AS
J Rheumatol; 1994 Mar; 21(3):473-5. PubMed ID: 8006891
[TBL] [Abstract][Full Text] [Related]
35. Differing specificities for 4-aminofolate analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action.
Rumberger BG; Barrueco JR; Sirotnak FM
Cancer Res; 1990 Aug; 50(15):4639-43. PubMed ID: 2369741
[TBL] [Abstract][Full Text] [Related]
36. Antitumor efficacy of classical non-polyglutamylatable antifolates that inhibit dihydrofolate reductase.
Abraham A; Nair MG; McGuire JJ; Galivan J; Kisliuk RL; Vishnuvajjala BR
Adv Exp Med Biol; 1993; 338():663-6. PubMed ID: 8304202
[No Abstract] [Full Text] [Related]
37. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
38. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts.
Tedeschi PM; Kathari YK; Farooqi IN; Bertino JR
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1029-32. PubMed ID: 25205429
[TBL] [Abstract][Full Text] [Related]
39. Prediction of antifolate efficacy in a rat sarcoma model.
Li WW; Lin JT; Chang YM; Schweitzer B; Bertino JR
Int J Cancer; 1991 Sep; 49(2):234-8. PubMed ID: 1831805
[TBL] [Abstract][Full Text] [Related]
40. Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.
Kastrup IB; Worm J; Ralfkiaer E; Hokland P; Guldberg P; Grønbaek K
Eur J Haematol; 2008 Jan; 80(1):61-6. PubMed ID: 18028428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
